Wednesday, September 21st
10:45am-12:15pm EDT


Topical Workshop




718 B

Angiotensin Receptor Signaling as a Pain Target: Bench, Bedside and Back-Translation

The major bioactive molecule in the renin-angiotensin system, the peptide hormone angiotensin II orchestrates many more processes than blood pressure alone. Angiotensin receptor agonists and antagonists have demonstrated efficacy in multiple disease models, particularly neuropathic pain states. This workshop will cover the background of angiotensin receptor signaling in the nervous and immune systems in the context of neuropathic pain, describe the insights gained from clinical trials using novel angiotensin receptor antagonists, and highlight current research efforts focused on understanding the functions of angiotensin peptides and their receptors in inflammation, tissue repair and chronic neuropathic pain.


10:45am EDT12:15pm EDT

Highly-Selective Small Molecule AT2 Receptor Antagonists Alleviate Neuropathic Pain in Rodent Pain Models

Tracks: Mechanisms
Categories: Topical Workshop
Presented By: Prof. Maree T. Smith

Prof. Smith will provide an overview of the preclinical research that led to the discovery of the angiotensin AT2 receptor as a first-in-class pain target, and subsequent development of molecules that have entered clinical trials.

10:45am EDT12:15pm EDT

Neuroimmune Interactions and Angiotensin Receptor Signaling in Neuropathic Pain and Beyond

Tracks: Mechanisms
Categories: Topical Workshop
Presented By: Andrew J. Shepherd

Andrew Shepherd will provide a summary of ongoing efforts to delineate the mechanisms that drive angiotensin receptor signaling at sites of tissue damage, and pre-clinical studies that test the utility of repurposing existing drugs (such as antihypertensives) as analgesics.

10:45am EDT12:15pm EDT

Targeting Angiotensin Receptor Signaling for Neuropathic Pain: Clinical Trials and the Development Landscape

Tracks: Mechanisms
Categories: Topical Workshop

Andrew Rice will guide the audience through the three published multicentre clinical trials that examined angiotensin receptor signaling for the treatment of neuropathic pain. He will contextualize the efficacy signals from the trials against the data from existing therapies for neuropathic pain.

Rice A.S.C., Dworkin R.H., McCarthy T.D., Anand P., Bountra C., McCloud P.I., Hill J., Cutter G., Kitson, G., Desem, N. & Raff M. A novel target and treatment for post herpetic neuralgia: EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist studied in a double-blind, placebo-controlled, randomised phase2 clinical trial. The Lancet 2014;383:1637-1647

Rice ASC, Dworkin RH, Finnerup NB, Attal N, Anand P, Freeman R, Piaia A, Callegari F, Doerr C, Mondal S, Narayanan N, Ecochard L, Flossbach F & Pandhi S. Efficacy and safety of EMA401 in peripheral neuropathic pain: Results of two randomised, double-blind, phase 2 studies in patients with postherpetic neuralgia and painful diabetic neuropathy. PAIN 2021;162:2578-2589 .


Professor Andrew SC Rice

Professor of Pain Research
Imperial College London

Andrew J. Shepherd

Assistant Professor
MD Anderson Cancer Center

Prof. Maree T. Smith

Director, CIPDD
The University of Queensland